Somewhat Positive Press Coverage Somewhat Unlikely to Affect Sucampo Pharmaceuticals (SCMP) Stock Price
Media coverage about Sucampo Pharmaceuticals (NASDAQ:SCMP) has been trending somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sucampo Pharmaceuticals earned a news sentiment score of 0.23 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.8694191922856 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news articles that may have effected Accern’s analysis:
- Sucampo Pharmaceuticals, Inc. (SCMP) Insider Buys $49,820.00 in Stock (americanbankingnews.com)
- Sucampo Pharmaceuticals, Inc. (SCMP) crosses 50- SMA down along -0.66% – Street Observer (press release) (streetobserver.com)
- Drug Makers Stock Performance Review — DURECT, Sucampo Pharma, Apricus Biosciences, and MEI Pharma – Markets Insider (markets.businessinsider.com)
- Sucampo Pharmaceuticals, Inc. to Post FY2021 Earnings of $1.78 Per Share, Jefferies Group Forecasts (NASDAQ:SCMP) (americanbankingnews.com)
- Sucampo Pharmaceuticals, Inc. (SCMP) Given a $30.00 Price Target at Roth Capital (americanbankingnews.com)
A number of equities research analysts recently commented on the stock. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 4th. ValuEngine raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Maxim Group set a $23.00 target price on shares of Sucampo Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 2nd. BidaskClub cut shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Roth Capital set a $30.00 target price on shares of Sucampo Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Sucampo Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $17.63.
Sucampo Pharmaceuticals (SCMP) traded up 0.48% on Monday, hitting $10.45. 465,408 shares of the company’s stock were exchanged. Sucampo Pharmaceuticals has a 12-month low of $9.30 and a 12-month high of $17.55. The company’s 50-day moving average price is $10.58 and its 200-day moving average price is $10.73. The company’s market cap is $482.73 million.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.06. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The business had revenue of $59.90 million during the quarter, compared to analysts’ expectations of $56.44 million. During the same quarter in the prior year, the business posted $0.24 EPS. The company’s revenue for the quarter was up 15.3% on a year-over-year basis. Analysts forecast that Sucampo Pharmaceuticals will post $1.02 earnings per share for the current year.
In related news, insider Jones W. Bryan bought 4,700 shares of the stock in a transaction dated Friday, August 4th. The stock was acquired at an average price of $10.60 per share, for a total transaction of $49,820.00. Following the acquisition, the insider now owns 4,700 shares in the company, valued at approximately $49,820. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 4.13% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Sucampo Pharmaceuticals (SCMP) Stock Price” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/08/07/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-sucampo-pharmaceuticals-scmp-stock-price.html.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.